Nancy Dumont
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nancy Dumont has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Alice A. McDonald
Kymera Therapeutics, Inc. Watertown Massachusetts USA
26 shared publications - Ashwin M. Gollerkeri
Kymera Therapeutics, Inc. Watertown Massachusetts USA
26 shared publications - Dapeng Chen
Kymera Therapeutics, Inc. Watertown Massachusetts USA
26 shared publications - Eric W. Kuhn
Kymera Therapeutics, Inc., 500 North Beacon Street, Watertown, Massachusetts
26 shared publications - Jessica Filiatrault
Department of Radiation Oncology and Center for DNA Damage and Repair, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
26 shared publications - Jianfeng Qi
Kymera Therapeutics, Inc., 500 North Beacon Street, Watertown, Massachusetts
26 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Figure 2: Targeted proteomics analysis of MDM2 levels in MV4;11 AML cells shows that 150 nM KT 253 can achieve degradation of MDM2 within 1 hour posttreatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Figure 2: Targeted proteomics analysis of MDM2 levels in MV4;11 AML cells shows that 150 nM KT 253 can achieve degradation of MDM2 within 1 hour posttreatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Table 1: Cell lines and reagents
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Table 1: Cell lines and reagents
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 7 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Figure 7: A single dose of KT 253 shows strong single-agent activity in a venetoclax resistant patient-derived AML model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 7 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Figure 7: A single dose of KT 253 shows strong single-agent activity in a venetoclax resistant patient-derived AML model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Table 3: KT-253 shows picomolar growth inhibition potency compared with other MDM2 small molecule inhibitors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Table 3: KT-253 shows picomolar growth inhibition potency compared with other MDM2 small molecule inhibitors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Figure 5: A single dose of KT-253 more robustly induces p53 targets compared with exposure matched weekly dosing regimen.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Figure 5: A single dose of KT-253 more robustly induces p53 targets compared with exposure matched weekly dosing regimen.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Figure 4: A functional p53 is required for growth inhibition with KT-253.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Figure 4: A functional p53 is required for growth inhibition with KT-253.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Table 5: Activity of KT-253 in AML patient-derived xenograft models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Table 5: Activity of KT-253 in AML patient-derived xenograft models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Figure 3: Short term exposures with KT-253 sufficient for growth inhibition compared with MDM2 SMIs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Figure 3: Short term exposures with KT-253 sufficient for growth inhibition compared with MDM2 SMIs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Table 2: Genes and TaqMan Gene Expression Assay IDs used for RT-qPCR assays
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Table 2: Genes and TaqMan Gene Expression Assay IDs used for RT-qPCR assays
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Table 4: KT-253 shows potent growth inhibition and caspase activation across a panel of p53 wild-type hematologic cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
Supplemental Table 4: KT-253 shows potent growth inhibition and caspase activation across a panel of p53 wild-type hematologic cell lines.